Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1Phase 1 1

Status

Completed 4

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 3Tumor-Agnostic 1Lymphoid 1

Conditions

Keratosis, Actinic 2Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Keratosis 1Dermatitis, Contact 1Carcinoma 1

Interventions

Cyclophosphamide 641Bevacizumab 552Paclitaxel 534Carboplatin 533Cisplatin 480pembrolizumab 456Gemcitabine 422Docetaxel 415Rituximab 386Radiotherapy 373Dexamethasone 351Doxorubicin 330Nivolumab 308Fluorouracil 286Capecitabine 260Etoposide 245Prednisone 244Oxaliplatin 242Erlotinib Hydrochloride 242Cytarabine 233Lenalidomide 232Trastuzumab 226Pemetrexed 220Vincristine 212fludarabine phosphate 208Leucovorin 208Cetuximab 208Filgrastim 204Bortezomib 193Methotrexate 183

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Has results × Ointments × Clear all
NCT05741294 2025-02-20

A Study of Tirbanibulin on the Wellbeing of Participants With Actinic Keratoses

Almirall, S.A.

Phase 4 Completed
334 enrolled 12 charts
Dermatologic

Keratosis, Keratosis, Actinic

NCT03380026 2021-11-24

MIDAS

Rochester Skin Lymphoma Medical Group, PLLC

Phase 2 Completed
28 enrolled 8 charts
DermatologicLymphoid

Dermatitis, Contact, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous

NCT03083470 2019-05-15

Study of SOR007 Ointment for Actinic Keratosis

DFB Soria, LLC

Phase 2 Completed
33 enrolled 15 charts
Dermatologic

Keratosis, Actinic

NCT02587819 2016-04-14

Investigation of the Safety and Tolerability of BSCT (Anti-nf-P2X7) 10% Ointment

Biosceptre

Phase 1 Completed
21 enrolled 9 charts
Tumor-Agnostic

Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡